TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026
October 21, 2026 · 8:52 AM · NEW YORK
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced several updated poster presentations at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting. The presentations include seven-year follow up data from the ULTIMATE I & II trials, Phase 1 subcutaneous BRIUMVI data, Phase 3 ENHANCE trial data, an update from the ENABLE real world study, and more presentations highlighting BRIUMVI data. Additionally, the abstract is now available for the late-breaking oral presen...
- PublishedOctober 21, 2026 · 8:52 AM
- LocationNEW YORK
- IndustryScience
- LanguageEN
Published by Business Wire. Read the original announcement for the full release.
Read the full announcement →